Maintaining Treatment Beyond the Clinical Trial: A Mibavademab Case Study in Global Post-Trial Access Planning

• Using the mibavademab EAP as a case study to explore global post-trial access planning and treatment continuity
• Navigating differing regulatory requirements and access pathways across multiple countries
• Balancing governance, real-world data collection and cross-functional decisionmaking when implementing post-trial access globally

Speakers:

David Stein

Senior Director, Clinical Trial Management

Regeneron

Maggie Loughran

Manager, Medical Study Operations

Regeneron